IRCT2016112631104N1已完成未知
Comparison of pioglitazone with sitagliptin effect on glycemic state in patients with uncontrolled diabetes 2 using metformin and sulfonylureas
Vice Chancellor for research of Lorestan University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •patients with type 2 diabetes who are older than 18 years treated with 1500 mg metformin and 10-20mg sulfonylureas per day are included in the study. These patients should have HbA1c greater than 7 and fasting glucose greater than 126 mg / dL.
- •Exclusion criteria:
- •1) patients who have type 1 diabetes,
- •2) known case of heart disease and exertional dyspnea, grade 3 and 4
- •3) kidney disease (GFR <30),
- •4) ALT / AST more than 3 times normal
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patientsType 2 DiabetesJPRN-UMIN000004716Yokohama City Unuversity School of Medicine130
已完成
3 期
Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus SulfonylureaUncontrolled Type 2 Diabetes MellitusNCT03125694Tehran University of Medical Sciences250
进行中（未招募）
不适用
Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and an activated inflammationA randomized double-blinded phase II studyon-diabetic hypertensive patients with a hsCRP value > 1.0 mg/L < 10.0 mg/L and pretreated with ACE inhibitors for at least 12 weeks are eligible for study participation.MedDRA version: 8.1Level: LLTClassification code 10003601Term: AtherosclerosisEUCTR2006-004028-35-DETakeda Pharma GmbH
招募中
3 期
Effect of Pioglitazone and ClobetasolIRCT20210926052596N1Tehran University of Medical Sciences40
已完成
3 期
comparison the therapeutic effect of pioglitazone and carnitine to pioglitazone and vitamin E in patients with non alcoholic fatty liver diseaseIRCT20190701044062N8Tabriz University of Medical Sciences80